Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,577.90 +0.43%
EUR-USD 1.2579 0.1906%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 91.27 +0.45%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: -
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Chemgenex Pharmaceuticals Ltd

CXS:AU

Acquired

Chemgenex Pharmaceuticals Ltd (CXS:AU) was acquired by TEVA:IT


Company Profile

ChemGenex Pharmaceuticals Limited is a biotechnology medical research company. The Companresearches and develops, through licensing arrangements, testing and treatment for human cancer and for the detection and classification of insulin-dependent diabetes, obesity and depression and anxiety. The Company has operations in Australia and the United States.

Advertisement